Status:
UNKNOWN
Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia
Lead Sponsor:
Fundación Marques de Valdecilla
Collaborating Sponsors:
Centro de Investigación Biomédica en Red de Salud Mental
Instituto de Investigación Marqués de Valdecilla
Conditions:
Schizophrenia
Eligibility:
All Genders
15-60 years
Brief Summary
Schizophrenia is a severe and chronic mental disorder. The lifetime risk of schizophrenia is around 1%. Its course is chronic and frequently disabling. The keystone of schizophrenia treatment is antip...
Eligibility Criteria
Inclusion
- Patients followed up for 3 years in the First Episode Psychosis Clinical Program (PAFIP).
- 15-60 years.
- Living in the catchment area.
- Experiencing their first episode of psychosis.
- No prior treatment with antipsychotic medication or, if previously treated, a total life time of adequate antipsychotic treatment of less than 6 weeks.
- Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for brief psychotic disorder, schizophreniform disorder, schizophrenia, or schizoaffective disorder.
Exclusion
- Meeting DSM-IV criteria for drug dependence.
- Meeting DSM-IV criteria for mental retardation.
- Having a history of neurological disease or head injury.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02205437
Start Date
January 1 2015
End Date
December 1 2020
Last Update
January 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Marques de Valdecilla
Santander, Cantabria, Spain, 39008